TrialBlood2013

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Farhad Ravandi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.